Global Tyrosine Kinase JAK Inhibitors Market Research Report 2023(Status and Outlook)
Report Overview
Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.
These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.
In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.
The classification of Tyrosine Kinase JAK Inhibitors includes Tofacitinib, Ruxolitinib and Baricitinib, and the proportion of Ruxolitinib is about 56%.
Tyrosine Kinase JAK Inhibitors is widely used in Rheumatoid Arthritis (RA), Polycythemia Vera (PCV) and Myelofibrosis (MF). The most proportion of Tyrosine Kinase JAK Inhibitors is for Rheumatoid Arthritis (RA), and the proportion is about 37%.
North America is the largest consumption place, with a consumption market share nearly 56%. Following North America, Europe is the second largest consumption place with the consumption market share of 39%.
Market competition is intense. Pfizer, Incyte, Novartis, Eli Lilly are the leaders of the industry. Pfizer is the leader of this industry with about 42% market sharers.
The Global Tyrosine Kinase JAK Inhibitors Market Size was estimated at USD 18730.00 million in 2022 and is projected to reach USD 329088.40 million by 2029, exhibiting a CAGR of 50.60% during the forecast period.
Bosson Research’s latest report provides a deep insight into the global Tyrosine Kinase JAK Inhibitors market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Tyrosine Kinase JAK Inhibitors Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Tyrosine Kinase JAK Inhibitors market in any manner.
Global Tyrosine Kinase JAK Inhibitors Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Pfizer
Incyte
Novartis
Eli Lilly
Gilead
Sanofi
Galapagos
AbbVie
Vertex
Teva
Astellas Pharma
Celgene
CTI BioPharma
Market Segmentation (by Type)
Tofacitinib
Ruxolitinib
Baricitinib
Market Segmentation (by Application)
Cardiovascular
Gynecological and Obstetrical
Ophthalmologic
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Tyrosine Kinase JAK Inhibitors Market
Overview of the regional outlook of the Tyrosine Kinase JAK Inhibitors Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
- 1 Research Methodology and Statistical Scope
- 1.1 Market Definition and Statistical Scope of Tyrosine Kinase JAK Inhibitors
- 1.2 Key Market Segments
- 1.2.1 Tyrosine Kinase JAK Inhibitors Segment by Type
- 1.2.2 Tyrosine Kinase JAK Inhibitors Segment by Application
- 1.3 Methodology & Sources of Information
- 1.3.1 Research Methodology
- 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats
- 2 Tyrosine Kinase JAK Inhibitors Market Overview
- 2.1 Global Market Overview
- 2.1.1 Global Tyrosine Kinase JAK Inhibitors Market Size (M USD) Estimates and Forecasts (2018-2029)
- 2.1.2 Global Tyrosine Kinase JAK Inhibitors Sales Estimates and Forecasts (2018-2029)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region
- 3 Tyrosine Kinase JAK Inhibitors Market Competitive Landscape
- 3.1 Global Tyrosine Kinase JAK Inhibitors Sales by Manufacturers (2018-2023)
- 3.2 Global Tyrosine Kinase JAK Inhibitors Revenue Market Share by Manufacturers (2018-2023)
- 3.3 Tyrosine Kinase JAK Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4 Global Tyrosine Kinase JAK Inhibitors Average Price by Manufacturers (2018-2023)
- 3.5 Manufacturers Tyrosine Kinase JAK Inhibitors Sales Sites, Area Served, Product Type
- 3.6 Tyrosine Kinase JAK Inhibitors Market Competitive Situation and Trends
- 3.6.1 Tyrosine Kinase JAK Inhibitors Market Concentration Rate
- 3.6.2 Global 5 and 10 Largest Tyrosine Kinase JAK Inhibitors Players Market Share by Revenue
- 3.6.3 Mergers & Acquisitions, Expansion
- 4 Tyrosine Kinase JAK Inhibitors Industry Chain Analysis
- 4.1 Tyrosine Kinase JAK Inhibitors Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis
- 5 The Development and Dynamics of Tyrosine Kinase JAK Inhibitors Market
- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Market Restraints
- 5.5 Industry News
- 5.5.1 New Product Developments
- 5.5.2 Mergers & Acquisitions
- 5.5.3 Expansions
- 5.5.4 Collaboration/Supply Contracts
- 5.6 Industry Policies
- 6 Tyrosine Kinase JAK Inhibitors Market Segmentation by Type
- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Type (2018-2023)
- 6.3 Global Tyrosine Kinase JAK Inhibitors Market Size Market Share by Type (2018-2023)
- 6.4 Global Tyrosine Kinase JAK Inhibitors Price by Type (2018-2023)
- 7 Tyrosine Kinase JAK Inhibitors Market Segmentation by Application
- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Tyrosine Kinase JAK Inhibitors Market Sales by Application (2018-2023)
- 7.3 Global Tyrosine Kinase JAK Inhibitors Market Size (M USD) by Application (2018-2023)
- 7.4 Global Tyrosine Kinase JAK Inhibitors Sales Growth Rate by Application (2018-2023)
- 8 Tyrosine Kinase JAK Inhibitors Market Segmentation by Region
- 8.1 Global Tyrosine Kinase JAK Inhibitors Sales by Region
- 8.1.1 Global Tyrosine Kinase JAK Inhibitors Sales by Region
- 8.1.2 Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Region
- 8.2 North America
- 8.2.1 North America Tyrosine Kinase JAK Inhibitors Sales by Country
- 8.2.2 U.S.
- 8.2.3 Canada
- 8.2.4 Mexico
- 8.3 Europe
- 8.3.1 Europe Tyrosine Kinase JAK Inhibitors Sales by Country
- 8.3.2 Germany
- 8.3.3 France
- 8.3.4 U.K.
- 8.3.5 Italy
- 8.3.6 Russia
- 8.4 Asia Pacific
- 8.4.1 Asia Pacific Tyrosine Kinase JAK Inhibitors Sales by Region
- 8.4.2 China
- 8.4.3 Japan
- 8.4.4 South Korea
- 8.4.5 India
- 8.4.6 Southeast Asia
- 8.5 South America
- 8.5.1 South America Tyrosine Kinase JAK Inhibitors Sales by Country
- 8.5.2 Brazil
- 8.5.3 Argentina
- 8.5.4 Columbia
- 8.6 Middle East and Africa
- 8.6.1 Middle East and Africa Tyrosine Kinase JAK Inhibitors Sales by Region
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Egypt
- 8.6.5 Nigeria
- 8.6.6 South Africa
- 9 Key Companies Profile
- 9.1 Pfizer
- 9.1.1 Pfizer Tyrosine Kinase JAK Inhibitors Basic Information
- 9.1.2 Pfizer Tyrosine Kinase JAK Inhibitors Product Overview
- 9.1.3 Pfizer Tyrosine Kinase JAK Inhibitors Product Market Performance
- 9.1.4 Pfizer Business Overview
- 9.1.5 Pfizer Tyrosine Kinase JAK Inhibitors SWOT Analysis
- 9.1.6 Pfizer Recent Developments
- 9.2 Incyte
- 9.2.1 Incyte Tyrosine Kinase JAK Inhibitors Basic Information
- 9.2.2 Incyte Tyrosine Kinase JAK Inhibitors Product Overview
- 9.2.3 Incyte Tyrosine Kinase JAK Inhibitors Product Market Performance
- 9.2.4 Incyte Business Overview
- 9.2.5 Incyte Tyrosine Kinase JAK Inhibitors SWOT Analysis
- 9.2.6 Incyte Recent Developments
- 9.3 Novartis
- 9.3.1 Novartis Tyrosine Kinase JAK Inhibitors Basic Information
- 9.3.2 Novartis Tyrosine Kinase JAK Inhibitors Product Overview
- 9.3.3 Novartis Tyrosine Kinase JAK Inhibitors Product Market Performance
- 9.3.4 Novartis Business Overview
- 9.3.5 Novartis Tyrosine Kinase JAK Inhibitors SWOT Analysis
- 9.3.6 Novartis Recent Developments
- 9.4 Eli Lilly
- 9.4.1 Eli Lilly Tyrosine Kinase JAK Inhibitors Basic Information
- 9.4.2 Eli Lilly Tyrosine Kinase JAK Inhibitors Product Overview
- 9.4.3 Eli Lilly Tyrosine Kinase JAK Inhibitors Product Market Performance
- 9.4.4 Eli Lilly Business Overview
- 9.4.5 Eli Lilly Tyrosine Kinase JAK Inhibitors SWOT Analysis
- 9.4.6 Eli Lilly Recent Developments
- 9.5 Gilead
- 9.5.1 Gilead Tyrosine Kinase JAK Inhibitors Basic Information
- 9.5.2 Gilead Tyrosine Kinase JAK Inhibitors Product Overview
- 9.5.3 Gilead Tyrosine Kinase JAK Inhibitors Product Market Performance
- 9.5.4 Gilead Business Overview
- 9.5.5 Gilead Tyrosine Kinase JAK Inhibitors SWOT Analysis
- 9.5.6 Gilead Recent Developments
- 9.6 Sanofi
- 9.6.1 Sanofi Tyrosine Kinase JAK Inhibitors Basic Information
- 9.6.2 Sanofi Tyrosine Kinase JAK Inhibitors Product Overview
- 9.6.3 Sanofi Tyrosine Kinase JAK Inhibitors Product Market Performance
- 9.6.4 Sanofi Business Overview
- 9.6.5 Sanofi Recent Developments
- 9.7 Galapagos
- 9.7.1 Galapagos Tyrosine Kinase JAK Inhibitors Basic Information
- 9.7.2 Galapagos Tyrosine Kinase JAK Inhibitors Product Overview
- 9.7.3 Galapagos Tyrosine Kinase JAK Inhibitors Product Market Performance
- 9.7.4 Galapagos Business Overview
- 9.7.5 Galapagos Recent Developments
- 9.8 AbbVie
- 9.8.1 AbbVie Tyrosine Kinase JAK Inhibitors Basic Information
- 9.8.2 AbbVie Tyrosine Kinase JAK Inhibitors Product Overview
- 9.8.3 AbbVie Tyrosine Kinase JAK Inhibitors Product Market Performance
- 9.8.4 AbbVie Business Overview
- 9.8.5 AbbVie Recent Developments
- 9.9 Vertex
- 9.9.1 Vertex Tyrosine Kinase JAK Inhibitors Basic Information
- 9.9.2 Vertex Tyrosine Kinase JAK Inhibitors Product Overview
- 9.9.3 Vertex Tyrosine Kinase JAK Inhibitors Product Market Performance
- 9.9.4 Vertex Business Overview
- 9.9.5 Vertex Recent Developments
- 9.10 Teva
- 9.10.1 Teva Tyrosine Kinase JAK Inhibitors Basic Information
- 9.10.2 Teva Tyrosine Kinase JAK Inhibitors Product Overview
- 9.10.3 Teva Tyrosine Kinase JAK Inhibitors Product Market Performance
- 9.10.4 Teva Business Overview
- 9.10.5 Teva Recent Developments
- 9.11 Astellas Pharma
- 9.11.1 Astellas Pharma Tyrosine Kinase JAK Inhibitors Basic Information
- 9.11.2 Astellas Pharma Tyrosine Kinase JAK Inhibitors Product Overview
- 9.11.3 Astellas Pharma Tyrosine Kinase JAK Inhibitors Product Market Performance
- 9.11.4 Astellas Pharma Business Overview
- 9.11.5 Astellas Pharma Recent Developments
- 9.12 Celgene
- 9.12.1 Celgene Tyrosine Kinase JAK Inhibitors Basic Information
- 9.12.2 Celgene Tyrosine Kinase JAK Inhibitors Product Overview
- 9.12.3 Celgene Tyrosine Kinase JAK Inhibitors Product Market Performance
- 9.12.4 Celgene Business Overview
- 9.12.5 Celgene Recent Developments
- 9.13 CTI BioPharma
- 9.13.1 CTI BioPharma Tyrosine Kinase JAK Inhibitors Basic Information
- 9.13.2 CTI BioPharma Tyrosine Kinase JAK Inhibitors Product Overview
- 9.13.3 CTI BioPharma Tyrosine Kinase JAK Inhibitors Product Market Performance
- 9.13.4 CTI BioPharma Business Overview
- 9.13.5 CTI BioPharma Recent Developments
- 10 Tyrosine Kinase JAK Inhibitors Market Forecast by Region
- 10.1 Global Tyrosine Kinase JAK Inhibitors Market Size Forecast
- 10.2 Global Tyrosine Kinase JAK Inhibitors Market Forecast by Region
- 10.2.1 North America Market Size Forecast by Country
- 10.2.2 Europe Tyrosine Kinase JAK Inhibitors Market Size Forecast by Country
- 10.2.3 Asia Pacific Tyrosine Kinase JAK Inhibitors Market Size Forecast by Region
- 10.2.4 South America Tyrosine Kinase JAK Inhibitors Market Size Forecast by Country
- 10.2.5 Middle East and Africa Forecasted Consumption of Tyrosine Kinase JAK Inhibitors by Country
- 11 Forecast Market by Type and by Application (2024-2029)
- 11.1 Global Tyrosine Kinase JAK Inhibitors Market Forecast by Type (2024-2029)
- 11.1.1 Global Forecasted Sales of Tyrosine Kinase JAK Inhibitors by Type (2024-2029)
- 11.1.2 Global Tyrosine Kinase JAK Inhibitors Market Size Forecast by Type (2024-2029)
- 11.1.3 Global Forecasted Price of Tyrosine Kinase JAK Inhibitors by Type (2024-2029)
- 11.2 Global Tyrosine Kinase JAK Inhibitors Market Forecast by Application (2024-2029)
- 11.2.1 Global Tyrosine Kinase JAK Inhibitors Sales (K MT) Forecast by Application
- 11.2.2 Global Tyrosine Kinase JAK Inhibitors Market Size (M USD) Forecast by Application (2024-2029)
- 12 Conclusion and Key Findings
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook